Prognostic factors effective on survival of patients with glioblastoma: Anadolu Medical Center experience
The aim of this study is to offer survival following radiation therapy using intensity-modulated radiotherapy or volumetric arc therapy with temozolomide in patients with glioblastoma. Ninety-two previously treated patients with high-grade glioma (World Health Organization [WHO] grade IV) were studi...
Gespeichert in:
| Veröffentlicht in: | Indian journal of cancer 2016-07, Vol.53 (3), p.382 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 382 |
| container_title | Indian journal of cancer |
| container_volume | 53 |
| creator | Guden, M Ayata, H B Ceylan, C Kilic, A Engin, K |
| description | The aim of this study is to offer survival following radiation therapy using intensity-modulated radiotherapy or volumetric arc therapy with temozolomide in patients with glioblastoma.
Ninety-two previously treated patients with high-grade glioma (World Health Organization [WHO] grade IV) were studied in Anadolu Medical Center, Department of Radiation Oncology, between January 2006 and July 2015. The diagnosis was established by pathology in all cases. The median age was 59 years (range, 19-86 years). The median tumor diameter was 45 mm, and the rate of the multicentric tumors was 16.3%. The location of the tumor was temporal in 33.7%, parietal in 14.1%, frontal in 23.9%, occipital in 9.8%, and others in 18.5%. The gross total and subtotal resection were performed in 60.9% of the patients, partial resection in 26.1%, and only stereotactic biopsy in 13.0% of the patients.
The median overall survival (OS) was 33.01 ± 4.76 months (95% confidence interval 25.64-40.38 months). 1, 2, and 5 years OS was 74.3%, 44.3%, and 31.8%, respectively. The median progression-free survival (PFS) was 27.36 ± 3.87 months (95% confidence interval 19.82-34.89 months). 1, 2, and 5 years PFS was 62.7%, 32.6%, and 27.2%, respectively. On univariate analysis, gender, extent of surgery, tumor size, Karnofsky performance status, and tumor suppressor gene (P53) were significant predictors of OS and PFS. On multivariate analysis, gender (PFS: P = 0.006, OS: P = 0.003), extent of surgery (PFS: P = 0.004, OS: P = 0.012), P53 (PFS: P = 0.003, OS: P = 0.021), and size of tumor (PFS: P = 0.005, OS: 0.012) remained significantly associated with PFS and OS. There is no statistically significant in OS and PFS between female and male (OS: log-rank: 0.79 P = 0.375, PFS: log-rank: 0.54 P = 0.465). PSF and OS were not significantly significant with total/near total resection compared with partial resection (PSF: P = 0.46 log-rank = 0.54, OS: P = 0.340 log-rank = 0.91). Patients with P53 50% value were compared and results were not found statistically significant (PSF: P = 0.917 log-rank = 0.01, OS: P = 0.892 log-rank = 0.02). For patients with tumor size |
| doi_str_mv | 10.4103/0019-509X.200664 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1875861671</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A483770748</galeid><sourcerecordid>A483770748</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-5be3c33d84cf39cd0658857ec321e054a00327fbce69640a4f326efa282028613</originalsourceid><addsrcrecordid>eNptks-PEyEUx4nRuLV692RITLxNZYABxlvT-CtZowdNvBHKPFo2M1CBqfrfS9N1s5s0HF4Cnw-E930IvWzJireEvSWk7ZuO9D9XlBAh-CO0aPteNVxK_hgt7o6v0LOcbwihjHL1FF1RRTnnolsg_y3FXYi5eIudsSWmjME5sMUfAceA85yO_mhGHB0-mOIhlIx_-7LHu9HH7WhyiZN5h9fBDHGc8RcYvK34poKQMPw5QKqShefoiTNjhhe3dYl-fHj_ffOpuf768fNmfd1YLlhpui0wy9iguHWstwMRnVKdBMtoC6TjhhBGpdtaEL3gxHDHqABn6pcIVaJlS_T6fO8hxV8z5KJv4pxCfVK3SnYVEfIetTMjaB9cLMnYyWer11wxKYmsZYmaC9QOAiQzxgDO1-0H_OoCX9cAk7cXhTf3hD2YsexzbWPxMeSHIDmDNsWcEzh9SH4y6a9uiT7Ngj6FrU9h6_MsVOXVbSPm7QTDnfA_fPYPkuOsqQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1875861671</pqid></control><display><type>article</type><title>Prognostic factors effective on survival of patients with glioblastoma: Anadolu Medical Center experience</title><source>MEDLINE</source><source>Medknow Open Access Medical Journals</source><source>Bioline International</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Guden, M ; Ayata, H B ; Ceylan, C ; Kilic, A ; Engin, K</creator><creatorcontrib>Guden, M ; Ayata, H B ; Ceylan, C ; Kilic, A ; Engin, K</creatorcontrib><description>The aim of this study is to offer survival following radiation therapy using intensity-modulated radiotherapy or volumetric arc therapy with temozolomide in patients with glioblastoma.
Ninety-two previously treated patients with high-grade glioma (World Health Organization [WHO] grade IV) were studied in Anadolu Medical Center, Department of Radiation Oncology, between January 2006 and July 2015. The diagnosis was established by pathology in all cases. The median age was 59 years (range, 19-86 years). The median tumor diameter was 45 mm, and the rate of the multicentric tumors was 16.3%. The location of the tumor was temporal in 33.7%, parietal in 14.1%, frontal in 23.9%, occipital in 9.8%, and others in 18.5%. The gross total and subtotal resection were performed in 60.9% of the patients, partial resection in 26.1%, and only stereotactic biopsy in 13.0% of the patients.
The median overall survival (OS) was 33.01 ± 4.76 months (95% confidence interval 25.64-40.38 months). 1, 2, and 5 years OS was 74.3%, 44.3%, and 31.8%, respectively. The median progression-free survival (PFS) was 27.36 ± 3.87 months (95% confidence interval 19.82-34.89 months). 1, 2, and 5 years PFS was 62.7%, 32.6%, and 27.2%, respectively. On univariate analysis, gender, extent of surgery, tumor size, Karnofsky performance status, and tumor suppressor gene (P53) were significant predictors of OS and PFS. On multivariate analysis, gender (PFS: P = 0.006, OS: P = 0.003), extent of surgery (PFS: P = 0.004, OS: P = 0.012), P53 (PFS: P = 0.003, OS: P = 0.021), and size of tumor (PFS: P = 0.005, OS: 0.012) remained significantly associated with PFS and OS. There is no statistically significant in OS and PFS between female and male (OS: log-rank: 0.79 P = 0.375, PFS: log-rank: 0.54 P = 0.465). PSF and OS were not significantly significant with total/near total resection compared with partial resection (PSF: P = 0.46 log-rank = 0.54, OS: P = 0.340 log-rank = 0.91). Patients with P53 <50% value and patients with P53 >50% value were compared and results were not found statistically significant (PSF: P = 0.917 log-rank = 0.01, OS: P = 0.892 log-rank = 0.02). For patients with tumor size <0 mm, small tumor size did not improve the PSF and OS (PSF: P = 0.291 log-rank = 1.11, OS: P = 0.288 log-rank = 1.13).
Ninety-two previously treated patients with high-grade glioma (WHO Grade IV) were evaluated with multivariate analysis. Gender, extent of surgery, P53, and tumor size were found as prognostic factors affecting on survival.</description><identifier>ISSN: 0019-509X</identifier><identifier>EISSN: 1998-4774</identifier><identifier>DOI: 10.4103/0019-509X.200664</identifier><identifier>PMID: 28244465</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Alkylating - therapeutic use ; Care and treatment ; Dacarbazine - analogs & derivatives ; Dacarbazine - therapeutic use ; Female ; Glioblastoma - drug therapy ; Glioblastomas ; Humans ; Male ; Medical centers ; Medical research ; Middle Aged ; Patient outcomes ; Prognosis ; Radiation (Physics) ; Radiotherapy ; Retrospective Studies ; Survival Analysis ; Young Adult</subject><ispartof>Indian journal of cancer, 2016-07, Vol.53 (3), p.382</ispartof><rights>COPYRIGHT 2016 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt Ltd Jul-Sep 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-5be3c33d84cf39cd0658857ec321e054a00327fbce69640a4f326efa282028613</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28244465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guden, M</creatorcontrib><creatorcontrib>Ayata, H B</creatorcontrib><creatorcontrib>Ceylan, C</creatorcontrib><creatorcontrib>Kilic, A</creatorcontrib><creatorcontrib>Engin, K</creatorcontrib><title>Prognostic factors effective on survival of patients with glioblastoma: Anadolu Medical Center experience</title><title>Indian journal of cancer</title><addtitle>Indian J Cancer</addtitle><description>The aim of this study is to offer survival following radiation therapy using intensity-modulated radiotherapy or volumetric arc therapy with temozolomide in patients with glioblastoma.
Ninety-two previously treated patients with high-grade glioma (World Health Organization [WHO] grade IV) were studied in Anadolu Medical Center, Department of Radiation Oncology, between January 2006 and July 2015. The diagnosis was established by pathology in all cases. The median age was 59 years (range, 19-86 years). The median tumor diameter was 45 mm, and the rate of the multicentric tumors was 16.3%. The location of the tumor was temporal in 33.7%, parietal in 14.1%, frontal in 23.9%, occipital in 9.8%, and others in 18.5%. The gross total and subtotal resection were performed in 60.9% of the patients, partial resection in 26.1%, and only stereotactic biopsy in 13.0% of the patients.
The median overall survival (OS) was 33.01 ± 4.76 months (95% confidence interval 25.64-40.38 months). 1, 2, and 5 years OS was 74.3%, 44.3%, and 31.8%, respectively. The median progression-free survival (PFS) was 27.36 ± 3.87 months (95% confidence interval 19.82-34.89 months). 1, 2, and 5 years PFS was 62.7%, 32.6%, and 27.2%, respectively. On univariate analysis, gender, extent of surgery, tumor size, Karnofsky performance status, and tumor suppressor gene (P53) were significant predictors of OS and PFS. On multivariate analysis, gender (PFS: P = 0.006, OS: P = 0.003), extent of surgery (PFS: P = 0.004, OS: P = 0.012), P53 (PFS: P = 0.003, OS: P = 0.021), and size of tumor (PFS: P = 0.005, OS: 0.012) remained significantly associated with PFS and OS. There is no statistically significant in OS and PFS between female and male (OS: log-rank: 0.79 P = 0.375, PFS: log-rank: 0.54 P = 0.465). PSF and OS were not significantly significant with total/near total resection compared with partial resection (PSF: P = 0.46 log-rank = 0.54, OS: P = 0.340 log-rank = 0.91). Patients with P53 <50% value and patients with P53 >50% value were compared and results were not found statistically significant (PSF: P = 0.917 log-rank = 0.01, OS: P = 0.892 log-rank = 0.02). For patients with tumor size <0 mm, small tumor size did not improve the PSF and OS (PSF: P = 0.291 log-rank = 1.11, OS: P = 0.288 log-rank = 1.13).
Ninety-two previously treated patients with high-grade glioma (WHO Grade IV) were evaluated with multivariate analysis. Gender, extent of surgery, P53, and tumor size were found as prognostic factors affecting on survival.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents, Alkylating - therapeutic use</subject><subject>Care and treatment</subject><subject>Dacarbazine - analogs & derivatives</subject><subject>Dacarbazine - therapeutic use</subject><subject>Female</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastomas</subject><subject>Humans</subject><subject>Male</subject><subject>Medical centers</subject><subject>Medical research</subject><subject>Middle Aged</subject><subject>Patient outcomes</subject><subject>Prognosis</subject><subject>Radiation (Physics)</subject><subject>Radiotherapy</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Young Adult</subject><issn>0019-509X</issn><issn>1998-4774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptks-PEyEUx4nRuLV692RITLxNZYABxlvT-CtZowdNvBHKPFo2M1CBqfrfS9N1s5s0HF4Cnw-E930IvWzJireEvSWk7ZuO9D9XlBAh-CO0aPteNVxK_hgt7o6v0LOcbwihjHL1FF1RRTnnolsg_y3FXYi5eIudsSWmjME5sMUfAceA85yO_mhGHB0-mOIhlIx_-7LHu9HH7WhyiZN5h9fBDHGc8RcYvK34poKQMPw5QKqShefoiTNjhhe3dYl-fHj_ffOpuf768fNmfd1YLlhpui0wy9iguHWstwMRnVKdBMtoC6TjhhBGpdtaEL3gxHDHqABn6pcIVaJlS_T6fO8hxV8z5KJv4pxCfVK3SnYVEfIetTMjaB9cLMnYyWer11wxKYmsZYmaC9QOAiQzxgDO1-0H_OoCX9cAk7cXhTf3hD2YsexzbWPxMeSHIDmDNsWcEzh9SH4y6a9uiT7Ngj6FrU9h6_MsVOXVbSPm7QTDnfA_fPYPkuOsqQ</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Guden, M</creator><creator>Ayata, H B</creator><creator>Ceylan, C</creator><creator>Kilic, A</creator><creator>Engin, K</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20160701</creationdate><title>Prognostic factors effective on survival of patients with glioblastoma: Anadolu Medical Center experience</title><author>Guden, M ; Ayata, H B ; Ceylan, C ; Kilic, A ; Engin, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-5be3c33d84cf39cd0658857ec321e054a00327fbce69640a4f326efa282028613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents, Alkylating - therapeutic use</topic><topic>Care and treatment</topic><topic>Dacarbazine - analogs & derivatives</topic><topic>Dacarbazine - therapeutic use</topic><topic>Female</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastomas</topic><topic>Humans</topic><topic>Male</topic><topic>Medical centers</topic><topic>Medical research</topic><topic>Middle Aged</topic><topic>Patient outcomes</topic><topic>Prognosis</topic><topic>Radiation (Physics)</topic><topic>Radiotherapy</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guden, M</creatorcontrib><creatorcontrib>Ayata, H B</creatorcontrib><creatorcontrib>Ceylan, C</creatorcontrib><creatorcontrib>Kilic, A</creatorcontrib><creatorcontrib>Engin, K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Indian journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guden, M</au><au>Ayata, H B</au><au>Ceylan, C</au><au>Kilic, A</au><au>Engin, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic factors effective on survival of patients with glioblastoma: Anadolu Medical Center experience</atitle><jtitle>Indian journal of cancer</jtitle><addtitle>Indian J Cancer</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>53</volume><issue>3</issue><spage>382</spage><pages>382-</pages><issn>0019-509X</issn><eissn>1998-4774</eissn><abstract>The aim of this study is to offer survival following radiation therapy using intensity-modulated radiotherapy or volumetric arc therapy with temozolomide in patients with glioblastoma.
Ninety-two previously treated patients with high-grade glioma (World Health Organization [WHO] grade IV) were studied in Anadolu Medical Center, Department of Radiation Oncology, between January 2006 and July 2015. The diagnosis was established by pathology in all cases. The median age was 59 years (range, 19-86 years). The median tumor diameter was 45 mm, and the rate of the multicentric tumors was 16.3%. The location of the tumor was temporal in 33.7%, parietal in 14.1%, frontal in 23.9%, occipital in 9.8%, and others in 18.5%. The gross total and subtotal resection were performed in 60.9% of the patients, partial resection in 26.1%, and only stereotactic biopsy in 13.0% of the patients.
The median overall survival (OS) was 33.01 ± 4.76 months (95% confidence interval 25.64-40.38 months). 1, 2, and 5 years OS was 74.3%, 44.3%, and 31.8%, respectively. The median progression-free survival (PFS) was 27.36 ± 3.87 months (95% confidence interval 19.82-34.89 months). 1, 2, and 5 years PFS was 62.7%, 32.6%, and 27.2%, respectively. On univariate analysis, gender, extent of surgery, tumor size, Karnofsky performance status, and tumor suppressor gene (P53) were significant predictors of OS and PFS. On multivariate analysis, gender (PFS: P = 0.006, OS: P = 0.003), extent of surgery (PFS: P = 0.004, OS: P = 0.012), P53 (PFS: P = 0.003, OS: P = 0.021), and size of tumor (PFS: P = 0.005, OS: 0.012) remained significantly associated with PFS and OS. There is no statistically significant in OS and PFS between female and male (OS: log-rank: 0.79 P = 0.375, PFS: log-rank: 0.54 P = 0.465). PSF and OS were not significantly significant with total/near total resection compared with partial resection (PSF: P = 0.46 log-rank = 0.54, OS: P = 0.340 log-rank = 0.91). Patients with P53 <50% value and patients with P53 >50% value were compared and results were not found statistically significant (PSF: P = 0.917 log-rank = 0.01, OS: P = 0.892 log-rank = 0.02). For patients with tumor size <0 mm, small tumor size did not improve the PSF and OS (PSF: P = 0.291 log-rank = 1.11, OS: P = 0.288 log-rank = 1.13).
Ninety-two previously treated patients with high-grade glioma (WHO Grade IV) were evaluated with multivariate analysis. Gender, extent of surgery, P53, and tumor size were found as prognostic factors affecting on survival.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>28244465</pmid><doi>10.4103/0019-509X.200664</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0019-509X |
| ispartof | Indian journal of cancer, 2016-07, Vol.53 (3), p.382 |
| issn | 0019-509X 1998-4774 |
| language | eng |
| recordid | cdi_proquest_journals_1875861671 |
| source | MEDLINE; Medknow Open Access Medical Journals; Bioline International; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents, Alkylating - therapeutic use Care and treatment Dacarbazine - analogs & derivatives Dacarbazine - therapeutic use Female Glioblastoma - drug therapy Glioblastomas Humans Male Medical centers Medical research Middle Aged Patient outcomes Prognosis Radiation (Physics) Radiotherapy Retrospective Studies Survival Analysis Young Adult |
| title | Prognostic factors effective on survival of patients with glioblastoma: Anadolu Medical Center experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T08%3A12%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20factors%20effective%20on%20survival%20of%20patients%20with%20glioblastoma:%20Anadolu%20Medical%20Center%20experience&rft.jtitle=Indian%20journal%20of%20cancer&rft.au=Guden,%20M&rft.date=2016-07-01&rft.volume=53&rft.issue=3&rft.spage=382&rft.pages=382-&rft.issn=0019-509X&rft.eissn=1998-4774&rft_id=info:doi/10.4103/0019-509X.200664&rft_dat=%3Cgale_proqu%3EA483770748%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1875861671&rft_id=info:pmid/28244465&rft_galeid=A483770748&rfr_iscdi=true |